SCHEMBL23975165

SCHEMBL23975165

CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](C)C[C@]12C

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.85
HIF1A Q16665 5/20 0.85
SMN1; SMN2 Q16637 4/20 0.85
CYP2C9 P11712 4/20 0.85
LMNA P02545 4/20 0.85
NR3C1 P04150 3/20 0.85
PGR P06401 2/20 0.85
SERPINA6 P08185 3/20 0.74
HSD11B2 P80365 4/20 0.58
NR3C2 P08235 3/20 0.58
HSD11B1 P28845 2/20 0.58
ALDH1A1 P00352 4/20 0.56
TSHR P16473 3/20 0.56
HSD17B10 Q99714 1/20 0.56
SHBG P04278 2/20 0.56
CYP19A1 P11511 2/20 0.56
MAPT P10636 3/20 0.53
MAPK1 P28482 2/20 0.53
CYP2C19 P33261 2/20 0.53
MEN1 O00255 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Medrysone SCHEMBL4493 0.92 CYP3A4 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
Medrysone SCHEMBL12998543 0.92 CYP3A4 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
Medrysone SCHEMBL3048275 0.92 CYP3A4 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
Medrysone SCHEMBL13054978 0.92 CYP3A4 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
Medrysone SCHEMBL29866793 0.92 CYP3A4 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
Medrysone SCHEMBL840781 0.88 CYP3A4 (0.93) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
SCHEMBL20814164 0.85 SERPINA6 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
SCHEMBL19510152 0.85 SERPINA6 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
SCHEMBL13981876 0.85 SERPINA6 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA
SCHEMBL15873848 0.85 SERPINA6 (1.00) CYP3A4HIF1ASMN1; SMN2CYP2C9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021220061-A2 HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS RIPPLE THERAPEUTICS CORPORATION (CA) 2021-11-04 WO disclosed